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Abstract
In order to understand the role of plasma proteins in the rapid liver clearance of dextran-coated
superparamagnetic iron oxide (SPIO) in vivo, we analyzed the full repertoire of SPIO-binding blood
proteins using novel two-dimensional differential mass spectrometry approach. The identified
proteins showed specificity for surface domains of the nanoparticles: mannan-binding lectins bound
to the dextran coating, histidine-rich glycoprotein and kininogen bound to the iron oxide part, and
the complement lectin and contact clotting factors were secondary binders. Nanoparticle clearance
studies in knockout mice suggested that these proteins, as well as several previously identified
opsonins, do not play a significant role in the SPIO clearance. However, both the dextran coat and
the iron oxide core remained accessible to specific probes after incubation of SPIO in plasma,
suggesting that the nanoparticle surface could be available for recognition by macrophages,
regardless of protein coating. These data provide guidance to rational design of bioinert, long-
circulating nanoparticles.
1 Introduction
There is an increasing interest in medical applications of nanomaterials. In this regard, thorough
understanding of interactions of nanomaterials with the body milieu is mandatory. When
nanomaterials are injected into the blood stream, extensive interactions with plasma proteins,
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cells, and other blood components take place (reviewed by Moghimi [1]). Liposomes are one
example of nanocarriers where such interactions have been studied in detail. Phospholipids in
the outer bilayer of liposomes attract some known opsonins such as immunoglobulins and
complement [2,3], and other plasma components such as lipoproteins [4]. These events have
been shown to be important for clearance of liposomes by reticuloendothelial macrophages
that reside in the liver and spleen.
Dextran-coated superparamagnetic iron oxide nanoparticles (SPIO) are widely used as
magnetic resonance imaging contrast agents in the clinic (e.g., Ferridex™). These particles
consist of two main chemical components: crystalline iron oxide core (magnetite) and low
molecular weight dextran (~10 kDa). Some types of SPIO nanoparticles have been reported to
exhibit prolonged circulation times, either due to their ultrasmall size (less than 20 nm) [5] or
extensive surface crosslinking and PEGylation [6,7]. Larger SPIO (50-150 nm: Ferridex,
Micromod SPIO, Ferumoxides) with unmodified dextran coating are rapidly eliminated from
circulation by the liver and spleen, and therefore these particles primarily enhance MR contrast
in these organs [8]. It is important to better understand the mechanisms of this rapid clearance
in order to design long-circulating (stealth) SPIO.
The mechanism whereby nanoparticles and liposomes accumulate in the liver and the spleen
could be related to the nature of proteins that adsorb onto the surface of systemically
administered nanoparticles [9]. It has been shown that dextran-iron oxide and dextran-poly
(isobutylcyanoacrylate) nanoparticles are extensively coated in plasma with known opsonins
such as complement, fibronectin and fibrinogen [10,11]. However, the significance of these
interactions in the nanoparticle clearance in vivo is not known. Some previous experiments
suggested that dextran-iron oxide nanoparticles could be directly recognized through a yet-to-
be-defined receptor mechanism, without plasma opsonin involvement [12]. The validity of this
last claim in vivo is difficult to prove or disprove, in view of the constant presence of plasma
proteins in the body.
In order to shed light on the role of plasma proteins in the SPIO clearance, we analyzed the
spectrum of plasma proteins that bind to the nanoparticles and examined the role of these
proteins as potential nanoparticle opsonins. In order to do that we developed a method for the
proteomic analysis of the nanoparticle plasma coating without washing steps. Our analysis
surprisingly showed the selectivity of plasma proteome towards SPIO surface dextran and
exposed iron oxide. Using knockout mice, we show that these attached plasma proteins are
unlikely to play a role in the in vivo clearance of SPIO. We further demonstrate that the plasma
proteins do not mask completely the surface dextran and iron oxide of the nanoparticles,
suggesting that the SPIO surface could be directly recognized by macrophages. This study
provides insight to the mechanisms of nanoparticle uptake and gives an incentive to further
understand the nanoparticle surface properties in order to design non-toxic stealth
nanoparticles.
2 Materials and Methods
2.1 Plasma protein binding to nanoparticles
Superparamagnetic dextran iron oxide nanoparticles (SPIO) from various sources were used
in this study. Amino-dextran SPIO of 50nm size were obtained from Micromod GmbH,
Germany, and were labeled with fluorescein isothiocyanate (Sigma) to block the amino groups
and to facilitate their detection with microscope. Alternatively, SPIO were prepared by the
published method (magnetic nanoworms [7]) with the exception that no crosslinking or
amination steps were performed. In both types of particles, the surface charge was similar (zeta
potential −4.95 mV and −0.77 mV for nanoworms and FITC-Micromod-SPIO, respectively).
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Mouse plasma was obtained from freshly drawn mouse blood by cardiac puncture using either
citrate or heparin as anticoagulant, and was stored at −80°C before the experiments. Two
hundred μg of SPIO were incubated with 300 μl of mouse plasma, containing 10 μl of Sigma
tissue protease inhibitor cocktail, for 10 min under vortexing at room temperature. The unbound
proteins were extensively washed away using MACS® Midi magnetic separation column
(Miltenyi Biotec) or using 4 rounds of ultracentrifugation and resuspension in PBS, and the
particles were boiled in 10% SDS for 60 min. Following this, iron oxide was pelleted using
Beckman TLA-100 ultracentrifuge (70,000g for 10 min) and the supernatant with the eluted
proteins precipitated in 5 volumes of ice cold acetone overnight at −20° C, washed and analyzed
on SDS-PAGE or submitted as a whole for LC-MS/MS. Protein concentration was measured
using Bio-Rad Protein assay. For two-dimensional mass spectrometry, nanoparticles were
incubated with plasma as described above, with the exception that no washing was performed
following the incubation. Particles were pelleted once to the bottom at 70,000×g for 7 min, the
supernatant was removed as much as possible, the pellet volume was measured by pipette
(usually <10 μl), and the pellet was incubated in 50 μl of 8M Urea/1M NaCl/1M imidazole at
80°C for 30 min. The particles were pelleted again and the supernatant was submitted as is for
2D mass spectrometry. The control was exactly the same volume of plasma, processed in
exactly the same way.
For immunoblotting, the following antibodies were used: goat polyclonal anti-mouse kallikrein
and goat polyclonal anti-mouse HPRG (R&D Systems), rat monoclonal anti-mouse MBL-A
(Abcam) and rabbit polyclonal anti-mouse HMWK (generated by the laboratory of Dr.
McCrae).
2.2 Protein identification and analysis using mass spectroscopy
The full details of sample preparation, the instrumental setup, data collection and analysis are
provided in the Supplemental Methods section. Briefly, for protein identification using one-
dimensional D LC/MS/MS, 5 μg of the protein were enzymatically cleaved by trypsin and the
automated Nano LC LTQ MS/MS (Thermo Scientific, Waltham, MA) was performed as
described by Salvesen et al [13]. For large-scale protein identification using two-dimensional
proteomics, 400 μg mouse plasma proteins were digested with trypsin as described in
Supplemental Methods, separated on SCX (strong cation exchange) column and each fraction
(24 total) was subsequently analyzed on LTQ-Orbitrap.
The MS/MS spectra were analyzed by Sorcerer 2 (Sage-N Research Inc.) with SEQUEST (v.
27, rev. 11) as the search program for peptide/protein identification. The relative abundance
of each identified protein in different samples were analyzed by QTools, our in-house
developed open source tool for automated differential peptide/protein spectral counting
analysis (http://sr.burnham.org/sr/homepage/proteomics/links.html).
2.3 Proteomic data filtering
At present there is no ideal method to statistically analyze the differential proteomic data from
few technical replicates. Our semi-arbitrary filtering approach was based on the recent
publication by Nesvizhskii and coworkers [14]. The protein hits in each replicate after the
spectral counting were filtered so that only enrichment ratios above 1.5 were included in the
analysis. To increase the sensitivity of identification to >80% , the threshold of spectral counts
for 1.5-2.0-fold enrichment was set to >20, and 2.0-4.0-fold enrichment was set to >10. For >
4-fold enrichment, the minimal threshold of spectral counts for each of the enriched protein
was set to 5. Such filtering allowed to reduce the number of hits to a manageable list of about
50 proteins. Then, the enriched hits shared by both replicates were extracted to combine a
common list of 24 proteins. The datasheets with the non-filtered and semi-filtered data are
provided in the Supplement.
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2.4 Probing the chemical domains on the nanoparticle surface
To quantify the binding of FITC-labeled anti-dextran antibody (Stem Cell Research), 50 μl of
1 μg/ml iron oxide was incubated with 10 μl of the antibody in presence of 50 μl PBS or
heparinized mouse plasma. After 10 min incubation at RT, the particles were pelleted at
70,000×g and the percent of the Ab remaining in the supernatant was measured by fluorescence,
using same concentration of the Ab in either PBS or 50% plasma, but without SPIO, as 100%.
Because of the absence of information on the concentration of the antibody, the difference
between the control and the sample supernatant fluorescence was used to calculate the relative
binding.
In order to determine the degree of exposure of iron on the nanoparticle surface, 10 μg of
histidine-rich D5 domain of high molecular weight kininogen (D5-GST fusion, from the
laboratory of Dr. McCrae) was immobilized on 100 μl of glutathione agarose beads
(Amersham). Ten micrograms of iron oxide were then preincubated with 50 μl PBS or mouse
plasma for 10 min and then added to the beads. The slurry was incubated for another 10 min
and washed 3 times with 1 ml PBS. The bound iron was measured using QuantiChrom Iron
Assay (BioAssay Systems) as described in the instructions for the kit.
2.5 Mouse experiments
All the animal work was reviewed and approved by Burnham Institute’s Animal Research
Committee or by institutional committees where the knockout experiments were performed.
The list of the sources of knockout mouse strains is provided in the Supplemental Methods.
Normal C57BL/6J mice were used as controls and were gender and age matched with the
corresponding knockout mice.
The animals were anesthetized with Avertin, and nanoparticles (4 mg Fe/kg body weight) were
injected into the tail vein in a total volume of up to 150 μl. Blood was collected from the
periorbital vein by heparinized capillaries at different time points, and plasma was separated
from cells by centrifugation at 5000 rpm for 2 min. Ten microliters of plasma were collected
to measure iron levels by QuantiChrom Assay. When fluorescently labeled nanoparticles were
used, plasma was diluted 100 times and FITC fluorescence was measured using LS-50B
spectrofluorimeter (Perkin-Elmer) or FUJI FLA-5100 scanner. The data were fitted into mono-
exponential decay curve using Prism 4 (GraphPad Software) to calculate half-lives in plasma.
For histological analysis of the nanoparticle uptake, the animals were sacrificed 3 h post-
injection by cervical dislodgement under anesthesia, and livers were dissected, fixed in
formalin, cryosectioned and analyzed by fluorescent microscope.
2.6 In vitro experiments using isolated Kupffer cells
Kupffer cells were isolated from collagenase-perfused mouse liver by a differential
centrifugation method [15]. Briefly, anesthetized mouse was perfused through the heart with
1% BSA/RPMI, followed by 7 ml of Sigma collagenase IV solution (0.5 mg/ml in 1% BSA/
RPMI) through hepatic portal vein. The liver was then excised, minced and incubated in
collagenase solution at 37°C for 15 minutes. The hepatocytes were depleted by centrifugations
at 30×g for 5 minutes three times. The resulting non-parenchymal cells, which are about 70%
Kupffer cells as verified by F4/80 immunostaining, was washed three times and used for further
experiments.
To test the nanoparticle uptake by cells, 20 μg SPIO were incubated with 100 μl of 1% BSA/
PBS, whole plasma, or SPIO opsonin-depleted plasma (by preincubation with 200 μg SPIO
and pelleting the particles using ultracentrifuge). Then, 1×106 Kupffer cells were incubated at
37°C for 1h with SPIO. All the samples were supplemented with 4 mM Ca++ and, for inhibition
of coagulation of plasma, 10 μM PPACK (Calbiochem) prior to mixing with SPIO. By the end
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of the incubation, the cells were washed in BSA/PBS 3 times, lysed with 10% SDS and iron
oxide uptake was quantified as described above. Alternatively, after the incubation with
nanoparticles the cells were seeded in slide chambers (NalgeNunc) to study the SPIO uptake
by microscopy.
3 Results
3.1 Proteomic analysis of opsonization of SPIO
To identify SPIO-binding proteins, we initially incubated the nanoparticles with mouse plasma,
removed unbound proteins by extensive washing, and then eluted the bound proteins (Fig. 1A).
Under these conditions, the nanoparticles absorbed as much as 1 mg protein per mg iron oxide.
Gel analysis showed significant enrichment of the nanoparticles with plasma proteins (Fig.
1B). It should be noted that the protein binding profiles were identical for all types of SPIO
nanoparticles, whether they were from commercial source or prepared in our laboratory.
Mass spectrometric identification of these eluted proteins from one such experiment is shown
in Table 1 (for complete proteomic data, see Supplementary Table 1). The most significant and
reproducible hits were histidine-proline rich glycoprotein (HPRG), high molecular weight
kininogen (HMWK), and plasma prekallikrein (KLK). The enrichment of these proteins on the
particles was striking, considering their relatively low abundance in plasma.
Fibronectin, vitronectin and C3 complement have been shown to bind to SPIO [11]. However,
C3 and fibronectin were not reproducibly present on plasma-treated SPIO in our mass
spectrometry experiments. Also, immunoglobulin detection in the eluted proteins was not
reproducible from experiment to experiment (not shown).
Minor variations in incubation and washing conditions could lead to carryover of non-bound
proteins in the SPIO binding assay we used. Alternatively, rigorous washing could remove
weakly interacting proteins, as has been observed with other types of nanoparticles [16]. In
order to identify all the bound proteins we decided to employ a procedure that eliminates the
bias of the washing steps (Fig. 1C, Methods). We incubated SPIO in plasma, quickly pelleted
the particles in an ultracentrifuge, and analyzed the proteins enriched in the SPIO pellet.
Because the proteins were present at their native concentration without washing steps to dilute
them throughout the experiment, the weakly bound proteins presumably stayed bound to the
particles. Because of the high complexity of the samples, we used a two-dimensional
chromatographic separation in order to resolve the mixture [17]. Differential counting software
was used to compare peptide intensities between the SPIO and control plasma samples.
According to Table 2 and Supplementary Table 2, many more significant proteins were
enriched on the nanoparticles, compared to the previous analysis. This process greatly enriched
some of the proteins that were otherwise undetectable when the particles were extensively
washed. There was a significant enrichment in the nanoparticle pellet of mannose-binding
lectins (MBLs), MBL-associated serine proteases (MASPs), apolipoproteins, beta-2
glycoprotein and clotting factors FXI and FXII. The enrichment was more then 7-fold for the
mannose-binding lectins A and C.
There was also some enrichment (1.2-1.5-fold) with downstream complement factors such as
C1q, C2, C5, clotting factors FIX, FX, and immunoglobulins (Supplemental Table 2) but there
was not enough statistical power in two replicates in order to consider these proteins
significantly enriched.
Hemoglobin and hemoglobin-binding hemopexin (proteoglycan-4) were also found to be
enriched on the SPIO (Supplemental Table 2), probably as a result of mildly hemolytic plasma,
but the significance of this enrichment in vivo is not clear. Some cellular proteins such as
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vinculin, tubulin-1 and talin-1were also enriched, possibly as a consequence of contamination
of plasma with cell debris, but it is not clear to what extent this phenomenon happens in the
circulation.
In order to confirm that some of the enriched proteins bind to SPIO, we performed western
blotting analysis of plasma supernatant after pelleting the nanoparticles with ultracentrifuge.
According to Fig. 1D, HPRG and HMWK are depleted from plasma but are also recoverable
from the washed nanoparticles. The dimeric form of MBL-A (but not the monomeric one,
which presumably has lower affinity) was also depleted from plasma after incubation with
SPIO. However, when SPIO pellet was washed extensively and the bound proteins were
analyzed, MBL-A was no longer detectable. These experiments underscore the problem of
weakly bound plasma proteins that could be missed during washing steps as suggested [16].
3.2 Interaction between SPIO surface domains and plasma proteins
The identified proteins showed remarkable specificity towards the surface domains of SPIO.
Thus, HPRG and HMWK possess extensive histidine-rich sequences [18]. These proteins are
known to bind to metal ions and negatively-charged surfaces through histidine-rich domains
[18,19]. In general, his-tagged proteins are routinely isolated using bivalent nickel chelates
[20]. Prekallikrein usually circulates in plasma in equimolar complex with HMWK, and binds
to foreign surfaces through kininogen [18]. To test whether these histidine-rich sequences have
high affinity for SPIO, we employed a peptide composed of 6 histidine residues. The His6
peptide showed strong binding to SPIO with 400 bound peptide molecules per mg iron (Fig
2A). Of two control peptides, CREKA showed no significant binding, while a positively
charged 34-amino acid peptide F3 that contains no histidine bound weakly. None of the
peptides bound to neutral dextran. These data suggest that histidine-rich sequences of plasma
HMWK and HPRG are responsible for D-SPIO binding, likely through surface-exposed iron
oxide. Loose dextran coating has been previously shown to incompletely mask the iron oxide
core of Ferumoxides [21].
To test whether the binding of HPRG and HMWK to SPIO could be inhibited by histidine-rich
peptide, we used a 30 kDa D5 domain of mouse kininogen-1 fused to GST. Precoating SPIO
with this protein completely abolished binding of HMWK and HPRG from plasma, while GST
or BSA did not have any effect on the protein binding (Fig. 2B).
In order to test the effect of plasma proteins on the accessibility of iron oxide core, we
immobilized D5 protein through the GST fusion domain onto glutathione-agarose beads, and
the beads were incubated with SPIO in the presence of 10-fold excess of plasma or in PBS.
According to Fig. 2C-D, the binding of SPIO to the D5-beads was only minimally reduced in
the presence of plasma, suggesting that plasma proteins do not coat completely the surface of
nanoparticles. Dextran did not bind to D5-agarose (not shown), confirming that the binding of
dextran-iron oxide nanoparticles to histidine-rich motifs took place through the exposed iron
oxide core.
Next, we probed the accessibility of dextran chains in plasma using an anti-dextran IgG.
Incubating the particles in plasma or in PBS did not significantly affect the binding of the
antibody to SPIO (Fig. 2E), indicating that dextran-binding plasma proteins, similar to the iron
oxide-binding proteins, do not shield the surface of the nanoparticles.
Importantly, the dextran coat and exposed iron oxide core domains showed no cross-reactivity:
D5 protein did not affect the binding of anti-dextran IgG to SPIO, and vice versa (Fig. 2D-E).
Simberg et al. Page 6
Biomaterials. Author manuscript; available in PMC 2010 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3.3 SPIO-binding proteins and plasma opsonins in nanoparticle clearance
We tested some of the SPIO-binding proteins revealed by the proteomics analyses and some
additional known opsonins for their effect on nanoparticle clearance and liver uptake by using
knockout mice for each protein. The data shown in Figure 3A, indicate that SPIO clearance is
normal in mice lacking C3, immunoglobulin, MBL-A, MBL-C, HPRG, HMWK and Fetuin-
A. Kallikrein does not bind to SPIO in the HMWK knockout mice (our unpublished
observation), so its role could be also excluded. Similarly, MASPs circulate in complex with
MLBs [22] and are not supposed to be recruited to the particle surface in the MBL-deficient
mice. In addition, mice null for other known opsonins such as fibronectin, fibrin, and
vitronectin were similar to wild-type controls in SPIO clearance (Fig. 3A). The liver is the
main organ responsible for nanoparticle uptake from the blood, and in accordance with earlier
results, selective depletion of Kupffer macrophages in the liver using clodronate liposomes
[23] produced a 5 to 10 fold increase in SPIO circulation time (Fig. 3A). The liver accumulation
of the nanoparticles was similar between knockout mice and controls, but was only minimal
in clodronate liposome-treated mice (Fig. 3B).
In vitro experiments using isolated Kupffer cells showed that the binding and uptake of SPIO
particles by Kupffer cells is unchanged or slightly inhibited in presence of whole mouse plasma,
or plasma that was depleted of SPIO-binding proteins (Figs. 4A-B). These combined data
provide no support for an involvement of plasma opsonins in SPIO removal from the blood,
and suggest that plasma protein coating does not prevent interaction with macrophage
receptors.
4 Discussion
Knowledge of the interactions of nanomaterials with host proteins is instrumental to
understanding the biological and medical effects of these materials. The most valid study of
nanoparticle opsonization would be to recover the injected nanoparticles from circulation and
analyze the repertoire of bound proteins, but it was not technically feasible. Using modern mass
spectrometry tools, we demonstrate in vitro that SPIO particles selectively bind certain plasma
proteins onto their surface.
We demonstrated the existence of three distinct sets of proteins that bind to SPIO (Fig. 5). A
set of iron oxide-binding proteins include strongly binding proteins HPRG and kininogen-1.
These proteins appear to bind to exposed parts of the negatively charged iron oxide core in
SPIO, directly through histidine-rich domains [18]. The binding of these proteins was clearly
selective, as indicated by the resistance of the interaction to stringent washing of the particles
and the high degree of enrichment relative to more abundant plasma proteins, such as albumin.
In addition, β-2 glycoprotein and apolipoprotein B are known to bind to negatively-charged
surfaces [24,25]. As such, it is likely that they also are attracted to iron oxide core, but additional
experiments would be necessary to confirm that.
Another set of proteins binds to dextran component of SPIO. These proteins were mostly
enriched in the pellet separated from plasma without washing of the particles. The enrichment
of some of the SPIO-bound minor plasma proteins was as high as 7-fold. Interestingly, some
of those enriched proteins were the mannose-binding lectins A and C. MBLs are known to bind
strongly to mannose polysaccharides on the bacterial surface [26], but may also interact with
the D-glucose units of the dextran coating, albeit less avidly. Immunoglobulins were also found,
although their enrichment was not as significant (Supplemental Table 2). Sugar-binding
antibodies in plasma have been reported before [27].
The last set of proteins appears to become associated with SPIO trough attachment to primary
binders. Thus, kallikrein binds to foreign surfaces through HMWK, and does not bind to SPIO
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in HMWK-deficient plasma (our unpublished observation). Some of the weakly-binding
proteins are also likely to be recruited through HMWK, such as coagulation factors XI and
XII. In a similar fashion, MBL-associated serine proteases (MASP-1 and MASP-2) circulate
in complexes with MBLs in plasma [26], suggesting that their binding to SPIO is indirect.
Interestingly, transferrin and albumin, the most abundant plasma protein, showed no significant
enrichment on the SPIO, even under these less stringent binding conditions. These results
reveal a previously unrecognized subtlety in protein binding to nanoparticles; proteins
significant to the biological effects of nanomaterials could easily be missed under certain
experimental conditions, producing incomplete “opsonome maps”.
We also provide data indicating that these bound plasma proteins are unlikely to promote SPIO
clearance by liver macrophages. Depending on the surface properties, both stimulatory and
inhibitory effects on nanoparticle uptake by serum have been previously reported [11,12,28,
29]. Because serum has undergone blood clotting, it may produce a somewhat different
nanoparticle coating than plasma, which we have studied. However, in view of the apparent
lack of any striking effect by plasma in vitro, and our results with knockout mice deficient in
various candidate opsonins, we suggest that plasma protein opsonization is not responsible for
the uptake of SPIO by the liver and spleen.
We favor the alternative hypothesis that there is a direct interaction between SPIO and cellular
receptors. Indeed, our experiments showed the lack of any masking effect of plasma on SPIO,
suggesting that the nanoparticle surface is still accessible for receptor recognition in vivo.
Pattern recognition receptors, such as Toll-like receptors, are known to bind bacterial and
fungal polysaccharides [30]. Scavenger receptors have been suggested to play a role in
macrophage uptake of several types of nanoparticles, including iron oxide and polystyrene
particles, and adenovirus [12,29,31]. Multiple receptors with overlapping specificities could
be also involved in the recognition of a single particle type. Receptor identification will be an
important future task, as it would allow rational design of inhibitors for the macrophage uptake
process.
The proteins that bind to the surface of nanoparticles could play a role in nanoparticle-induced
toxicity. MBLs and MASPs bound to the surface are known to activate the lectin-complement
pathway [26], while immunoglobulins can trigger the classical complement pathway. The
complement activation was previously reported for other types of nanoparticles coated with
dextran [32], but the underlying mechanism of such activation has not been explored.
In addition to complement activation, the undesirable effects of nanomaterials can include
thrombosis and inflammation [33]. The binding of kallikrein, kininogen, coagulation Factors
XI and XII onto SPIO surface could potentially initiate the activation of the intrinsic pathway
of blood clotting. We have previously described clotting in tumor vessels upon systemic
administration of SPIO that were targeted to tumors with a clot-binding peptide [34]. However,
the intravascular clotting was restricted to tumor vessels, although a major portion of the
particles were taken up by the liver and spleen, indicating that inherent clot-promoting activity,
if any, of the particles was not sufficient to initiate the clotting.
5 Conclusions
In this study, we demonstrate that dextran-coated iron oxide nanoparticles specifically interact
with metal-binding and sugar-binding plasma proteins. Despite coating with plasma proteins,
nanoparticles are cleared by resident liver and spleen macrophages through opsonin-
independent mechanism. This suggests that either dextran or exposed iron oxide could be
directly recognized by macrophages. The absorbed plasma proteins might be responsible for
toxic effects of nanoparticles. The results of this study explain the role of plasma proteins in
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the macrophage recognition of short-circulating SPIO and perhaps should not be extrapolated
to other types of SPIO such as crosslinked or PEGylated nanoparticles. These data are important
in designing SPIO with stealth-like properties and modifying the thrombogenic and
complement-activating potential of nanomaterials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Protein binding and effect of plasma proteins on SPIO clearance and macrophage uptake
A, Schematic representation of one-dimensional proteomic analysis of plasma proteins bound
to SPIO. B, Silver stained SDS-PAGE. Proteins were eluted from SPIO using the above
procedure and analyzed by LC-MS/MS (Table 1). Left lane, SeeBlue Plus2 standard size
marker (Invitrogen); right lane, eluted proteins. C, Schematic representation of two-
dimensional differential proteomics procedure used to identify plasma proteins that bind to
SPIO. See Methods for complete description of the procedure. D, Depletion of some of the
binding proteins from plasma after incubation with SPIO. The particles were incubated with
plasma as described in Methods, pelleted using ultracentrifuge and the supernatant was
analyzed by western blotting. Each gel included plasma proteins before incubation with SPIO
(PL), supernatant after pelleting the particles (Sup) and the particles (NP) washed by additional
4 rounds of ultracentrifugation with PBS. HMWK undergoes cleavage on the particle surface
(uncleaved size 120 kDa) to form activated kininogen (HKa). To detect MBL-A, the proteins
were separated and detected under non-reducing conditions. Note that MBL-A was not
detectable on SPIO, while it was depleted from plasma.
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Figure 2. Probing accessibility of dextran and iron oxide on SPIO
A, Binding of various peptide sequences to SPIO. A highly basic 34-amino acid peptide, F3
[35] (black bars), CREKA [34] (grey bars), and His-6 (dotted bars) were used. The peptides
were FITC-labeled to allow quantification. SPIO were incubated with the peptides for 10 min,
pelleted in an ultracentrifuge, and the amount of unbound and bound peptide was determined.
As control, peptides were incubated with dextran 500 kDa (Sigma), and the amount of bound
peptide was determined after separation of dextran by filter column. B, The nanoparticles were
incubated with mouse plasma only (lane 1), in the presence of histidine-rich domain 5 (D5) of
HMWK (lane 2) or with BSA (lane 3) for 10 min. Particle-bound proteins were eluted and
separated by SDS gel electrophoresis as described in Methods. C, Binding of SPIO to D5
immobilized on glutathione-agarose. See Methods section for description of the procedure.
Tube labels: 1, plain glutathione-agarose + SPIO particles (control); 2, D5-agarose + SPIO, 3,
D5-agarose + SPIO +plasma. D, Binding of particles to D5-agarose was quantified by the iron
assay (see Methods). SPIO were preincubated with either PBS, plasma or anti-dextran antibody
before addition to the beads. Note that plasma only partially reduces the binding to D5-agarose,
and that anti-dextran antibody does not interfere with the binding. Average of 3 experiments
is shown. E, Binding of FITC-labeled anti-dextran antibody to SPIO. SPIO were incubated
with either PBS, plasma or D5 fragment and subsequently with anti-dextran antibody. The
binding of the antibody was quantified as described in Methods. The D5 treatment and plasma
treatment had no effect on the antibody binding.
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Figure 3. Summary of circulation half-lives in mice
A, Knockout mice and matched wild type controls were injected with FITC-labeled or
unlabeled SPIO, and particle half-lives were determined as described in Methods. Mice injected
with clodronate liposomes served as a control for SPIO circulation time in mice with impaired
liver uptake (right bar). The values are averages from 2-3 mice per group. B, Liver histology
of some of the knockout mice sacrificed 3h post-injection of SPIO showing that there is no
difference in accumulation of FITC-labeled SPIO in Kupffer macrophages (green dots). Panel
labels: 1, HMWK-deficient; 2, wild type; 3, complement C3-deficient; 4, MBL-A/C-deficient;
5, wild type clodronate-treated. Objective: ×20.
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Figure 4. Cellular uptake of SPIO in isolated Kupffer cells
Non-labeled SPIO were preincubated with plasma or PBS and added to a suspension of isolated
Kupffer cells in PBS/BSA. A, The effect of plasma on nanoparticle uptake as determined by
microscopy. The particles were detected with a FITC-labeled anti-dextran antibody (green).
Macrophages were stained with F4/80 antibody (red). The cells were examined by fluorescent
microscopy. Objective, ×60. Upper panel, PBS-treated particles: lower panel, plasma-treated
particles. B, Quantification of SPIO uptake by mouse Kupffer cells in the presence or absence
of mouse plasma. As an additional control, mouse plasma depleted for SPIO-binding proteins
was used (right bar). Average of 2 experiments are shown.
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Figure 5.
Schematic representation of the assembly of SPIO-binding proteins on the NP surface.
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Table 1
Significant plasma proteins eluted from SPIO and identified by 1D LC-MS
Each protein entry shows the IPI (International Protein Index) number, link to the EMBL-EBI entry, and total
peptide spectral counts. The particles were incubated with plasma, washed extensively with PBS and the tightly
bound proteins were eluted as described in Methods. Additional proteomic data such as the peptides identified,
and peptide and protein probabilities are provided in the Supplemental Table 1. The experiment was repeated 3
times.
IPI # Spectralcount Protein identified Function
IPI00177214 2 IMMUNOGLOBULIN Immunoglobulin
IPI00131695 10 SERUM ALBUMIN. Carrier protein
IPI00320239 14 TETRANECTIN. Lectin-like, sugar-binding
IPI00113057 24 PLASMA KALLIKREIN. Serine protease, intrinsicclotting activator
IPI00114958 113 ISOFORM HMW OFKININOGEN-1. Surface-binding protein
IPI00322304 120 HISTIDINE-PROLINE RICHGLYCOPROTEIN (HPRG). Adaptor protein
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